10. Mass Spectrometry-Based Screening and Characterization of Protein–Ligand Complexes in Drug Discovery

  1. Michael L. Gross2,
  2. Guodong Chen3 and
  3. Birendra N. Pramanik4
  1. Christine L. Andrews,
  2. Michael R. Ziebell,
  3. Elliott Nickbarg and
  4. Xianshu Yang

Published Online: 23 SEP 2011

DOI: 10.1002/9781118116555.ch10

Protein and Peptide Mass Spectrometry in Drug Discovery

Protein and Peptide Mass Spectrometry in Drug Discovery

How to Cite

Andrews, C. L., Ziebell, M. R., Nickbarg, E. and Yang, X. (2011) Mass Spectrometry-Based Screening and Characterization of Protein–Ligand Complexes in Drug Discovery, in Protein and Peptide Mass Spectrometry in Drug Discovery (eds M. L. Gross, G. Chen and B. N. Pramanik), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118116555.ch10

Editor Information

  1. 2

    Washington University, St. Louis, MO, USA

  2. 3

    Bristol-Myers Squibb, Princeton, NJ, USA

  3. 4

    Merck Research Laboratories, Kenilworth, NJ, USA

Author Information

  1. Merck Research Laboratories, Cambridge, MA, USA

Publication History

  1. Published Online: 23 SEP 2011
  2. Published Print: 21 OCT 2011

ISBN Information

Print ISBN: 9780470258170

Online ISBN: 9781118116555

SEARCH

Keywords:

  • solution-based AS-MS methods;
  • receptor–ligand interactions;
  • enzyme activity assays

Summary

This chapter contains sections titled:

  • Introduction

  • Affinity Selection Mass Spectrometry (AS-MS)

  • Solution-Based AS-MS as Screening Technologies

  • Gas-Phase Interactions

  • Enzyme Activity Assays Using MS for Screening or Confirming Drug Candidates

  • Conclusions and Future Directions

  • References